Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05569577
Other study ID # FudanU2022-08-18
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 1, 2021
Est. completion date December 31, 2025

Study information

Verified date October 2022
Source Fudan University
Contact Hexia Xia, M.D.
Phone +86 13601843476
Email hexia_xia@fudan.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Luteal phase deficiency (LPD) accounts for most failures of assistant artificial reproduction (ART) and early pregnancy loss for patients with idiopathic hypogonadotropic hypogonadism (IHH). Luteal phase support (LPS) is one of the indispensable interventions in ART treatments for IHH patients, which includes progestin, estrogen, human chorionic gonadotropin (hCG), and GnRH agonists (GnRHa). We aim to verify additional hCG injection 48 hours following routine hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and dydrogesterone could improve clinical pregnancy rate, cumulative pregnancy rate, live birth rate and the prevalence of early pregnancy loss and ovarian hyperstimulation syndrome (OHSS) by an open labeled, prospective, and randomized clinical trial (RCT) in IHH patients in a single center.


Description:

Idiopathic hypogonadotropic hypogonadism (IHH) is a congenital disease caused by a variety of gene variants leading to dysfunction in the secretion of hypothalamic gonadotropin-releasing hormones (GnRHs), with a prevalence of 1:125 000 in females. Girls with IHH often suffer from lack of puberty onset, amenorrhea and infertility, complicated with psychological problems such as depression and anxiety, due to delayed diagnosis and inappropriate treatment. Luteal phase deficiency (LPD) accounts for most failures of assistant artificial reproduction (ART) and early pregnancy loss for IHH patients. We have reported a severe LPD during the early trimester in a case with secondary HH following craniopharyngioma resection and speculated similar LPD happen in IHH patients complicated with low clinical pregnancy rate and live birth rate. Therefore, luteal phase support (LPS) is one of the indispensable interventions in ART treatments for IHH patients, which includes progestin, estrogen, human chorionic gonadotropin (hCG), and GnRH agonists (GnRHa). We aim to verify additional hCG injection 48 hours following routine hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and dydrogesterone could improve clinical pregnancy rate, cumulative pregnancy rate, live birth rate and the prevalence of early pregnancy loss and ovarian hyperstimulation syndrome (OHSS) by an open labeled, prospective, and randomized clinical trial (RCT) in IHH patients in a single center of the Obstetrics and Gynecology Hospital Affiliated to Fudan University. The onset of patients' mental and psychological diseases such as depression and anxiety rely on their reproductive needs and pregnancy outcomes, which will also be investigated in the current study. Moreover, the effect of clinical interventions to improve pregnancy outcomes and emotional disorders would be discussed.


Recruitment information / eligibility

Status Recruiting
Enrollment 46
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Clinical diagnosis of IHH (primary amenorrhea (with or without a history of hormone supplementation therapy); basic LH levels <5IU/L, FSH<5IU/L or normal; no organic lesions in the hypothalamus and pituitary MRI). - Women of childbearing age who desire to get pregnant Exclusion Criteria: - Premature ovarian insufficiency or premature ovarian failure - Primary amenorrhea due to hypothalamic/pituitary lesions - Secondary amenorrhea

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Additional hCG injection
An additional hCG injection of 2000-5000IU would be given 48 hours following routine hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and dydrogesterone.
estrogen and dydrogesterone
estrogen and dydrogesterone

Locations

Country Name City State
China OB & GYN Hospital of Fudan University Shanghai Shanghai
China Obstetrics and Gynecology Hospital of Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Serum progesterone levels on Day 1, 7, and 14 after ovulation Serum progesterone levels is a symbol of luteal function 7 weeks
Primary Clinical pregnancy rate Defined as the presence of a gestational sac under ultrasonography 7 weeks
Primary Cumulative pregnancy rate Defined as a pregnancy with a detectable heart rate at 12 weeks of gestation or beyond. 12 weeks
Primary Live birth rate Defined as the number of deliveries that resulted in a live born neonate, expressed per 100 pregnancies. 42 weeks or beyond
Secondary Number of IHH patients ending in early pregnancy loss Early pregnancy loss is defined as the loss of a pregnancy prior to 12 weeks gestation 12 weeks
Secondary Number of IHH patients with ovarian hyperstimulation syndrome Ovarian hyperstimulation syndrome is defined as an exaggerated response to excess hormones. It usually occurs in women taking injectable hormone medications to stimulate the development of eggs in the ovaries. Ovarian hyperstimulation syndrome (OHSS) causes the ovaries to swell and become painful. 12 weeks or beyond
See also
  Status Clinical Trial Phase
Completed NCT02728440 - Effects of Gonadotropin Replacement Therapy on Metabolic Parameters in Patients With Hypogonadism N/A
Terminated NCT01165619 - Detailed Clinical, Biochemical and Genetic Characterization in Gonadotropin-releasing Hormone (GnRH) Deficiency Disorders N/A
Completed NCT01914172 - Health Needs of Patients With Kallmann Syndrome N/A
Completed NCT02042638 - The Effects of Gonadotropin Replacement Therapy in Patients With Hypogonadism N/A
Active, not recruiting NCT02310074 - Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism Phase 4
Completed NCT01758094 - Plasma RBP Levels in Patients With Idiopathic Hypogonadotrophic Hypogonadism N/A
Completed NCT01601327 - Effects of Medications in Patients With Hypogonadism Phase 4
Completed NCT00493961 - Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism Phase 1